Converging evidence continues to point towards Tau aggregation and pathology formation
as central events in the pathogenesis of Alzheimer's disease and other Tauopathies …

Given the high attrition rates, substantial costs and slow pace of new drug discovery and
development, repurposing of'old'drugs to treat both common and rare diseases is …

Alzheimer's disease (AD) is a neurodegenerative disorder with devastating symptoms,
including memory impairments and cognitive deficits. Hallmarks of AD pathology are …

Epileptic activity is frequently associated with Alzheimer's disease; this association has
therapeutic implications, because epileptic activity can occur at early disease stages and …

CNS disorders are on the rise despite advancements in our understanding of their
pathophysiological mechanisms. A major hurdle to the treatment of these disorders is the …

Tau protein plays a critical role in the assembly, stabilization, and modulation of
microtubules, which are important for the normal function of neurons and the brain. In …

Highlights•Publications for drug repositioning have drastically increased in past five
years.•Different types of drug repositioning and available resources have been …

ERK1 and ERK2 are key protein kinases that contribute to the Ras-Raf-MEK-ERK MAP
kinase signalling module. This pathway participates in the control of numerous processes …

Abstract Alzheimer's Disease (AD), the most prevalent neurodegenerative disease of aging,
affects one in eight older Americans. Nearly all drug treatments tested for AD today have …

The microtubule-associated protein tau and amyloid-β (Aβ) are key players in Alzheimer's
disease (AD). Aβ and tau are linked in a molecular pathway at the post-synapse with tau …